Following years of inadequate supply, a recently approved recombinant Bacillus Calmette-Guérin (rBCG) is now available in the United States to treat non-muscle invasive bladder cancer (NMIBC) patients.
Access to this vaccine may end the multi-year shortage of the TICE® BCG vaccine.
BCG Vaccine Shortage Ends in the United States
Trump Administration Reverses Plan to End Free COVID Test Program
By India Edwards HealthDay ReporterWEDNESDAY, Feb. 19, 2025 (HealthDay News) — The Trump administration changed course on Tuesday, deciding to keep the government’s free COVID test program running, just minutes …